33 -5 (91) 2026 - Xaydarova N.B., Artikova C.G. - ЭPIDEMIOLOGY AND PATHOGENESIS OF MAFLD: RELATIONSHIP WITH COMPONENTS OF METABOLIC SYNDROME

ЭPIDEMIOLOGY AND PATHOGENESIS OF MAFLD: RELATIONSHIP WITH COMPONENTS OF METABOLIC SYNDROME

Xaydarova N.B. - Andijan State Medical Institute

Artikova C.G. - Andijan State Medical Institute

Yunusova Z.V. - Andijan State Medical Institute

Isakova D.Z. - Andijan State Medical Institute

Resume

Metabolic dysfunction-associated fatty liver disease is a widespread chronic disease closely associated with the components of Metabolic syndrome. The main risk factors for the development of the disease include obesity, insulin resistance, type 2 diabetes mellitus, dyslipidemia, and arterial hypertension. The pathogenesis of MAFLD is based on disturbances in lipid and carbohydrate metabolism, chronic inflammation, and oxidative stress, which contribute to the progression of hepatic steatosis to steatohepatitis and fibrosis. Recent studies confirm that MAFLD is not only a liver disease but also a systemic metabolic disorder associated with an increased risk of cardiovascular complications. Early diagnosis, correction of metabolic abnormalities, and lifestyle modification play a key role in the prevention and treatment of this pathology.

Keywords: Metabolic dysfunction-associated fatty liver disease, Metabolic syndrome, obesity, insulin resistance, type 2 diabetes mellitus, dyslipidemia, hepatic steatosis, steatohepatitis, fibrosis, oxidative stress, chronic inflammation, epidemiology, pathogenesis.

First page

191

Last page

194

For citation:Xaydarova N.B., Artikova C.G., Yunusova Z.V., Isakova D.Z. - ЭPIDEMIOLOGY AND PATHOGENESIS OF MAFLD: RELATIONSHIP WITH COMPONENTS OF METABOLIC SYNDROME//New Day in Medicine 5(91)2026 191-194 https://newdayworldmedicine.com/en/new_day_medicine/5-91-2026

List of References

  1. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73(1):202–209. DOI:10.1016/j.jhep.2020.03.039.
  2. European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2023 update. J Hepatol. 2023;79(5):1175–1206. DOI:10.1016/j.jhep.2023.05.017.
  3. Mantovani A, Byrne CD, Zheng MH, Targher G. Risk of nonalcoholic fatty liver disease in individuals with type 1 diabetes: a meta-analysis. Diabetes Care. 2021;44(2):480–487. DOI:10.2337/dc20-1930.
  4. Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11–20. DOI:10.1038/nrgastro.2017.109.
  5. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84. DOI:10.1002/hep.28431.
  6. Mantovani A, Dalbeni A. NAFLD, MAFLD and cardiovascular diseases: A narrative review. World J Gastroenterol. 2022;28(24):2637–2651. DOI:10.3748/wjg.v28.i24.2637.

    file

    download